Nir Erdinest,Hadas Ben-Eli,Abraham Solomon
Nir Erdinest
Purpose of review: The spectrum of allergic eye diseases includes a variety of conditions, each characterized by complex immunopathologies.Antiallergic drugs, such as antihistamines and mast cell stabilizers, are often in...
Biologics and anaphylaxis [0.03%]
生物制剂与过敏性休克
Anna Sala-Cunill,Olga Luengo,Victoria Cardona
Anna Sala-Cunill
Purpose of review: The use of biologicals as therapeutic agents in oncology and other inflammatory diseases has dramatically increased during the last years. Due to their biological nature and inherent immunological activ...
Kara M Cavuoto,Allison C Stradiotto,Anat Galor
Kara M Cavuoto
Purpose of review: The purpose of this review is to provide an update regarding new and emerging data on the role of the ocular surface microbiome in allergic disease. ...
Miguel Blanca,Paul Whitaker
Miguel Blanca
Sara M Assaf,Nicola A Hanania
Sara M Assaf
Purpose of review: Asthma is a heterogenous disease associated with different phenotypes and endotypes. The unmet needs with severe asthma have led to the emergence of potential therapeutic targets beyond the existing the...
Mario Sánchez-Borges,Ignacio J Ansotegui
Mario Sánchez-Borges
Purpose of review: This article presents an update on the clinical pharmacology, mechanisms of action, and safety of second generation antihistamines (SGAHs). ...
Common and different roles of IL-4 and IL-13 in skin allergy and clinical implications [0.03%]
IL-4和IL-13在皮肤过敏反应中的相同及不同作用及其临床意义
Lennart M Roesner,Jana Zeitvogel,Annice Heratizadeh
Lennart M Roesner
Purpose of review: This review summarizes the mode of action of IL-4 and IL-13 in skin allergy, upcoming therapeutics and depicts key outcomes of the latest clinical trials. ...
Marta Sacchetti,Alice Bruscolini,Alessandro Lambiase
Marta Sacchetti
Purpose of review: During allergic reaction, nervous and immune systems mutually interact through release of mediators, including neurotrophic factors and nerve growth factor (NGF). These mediators modulate allergic react...
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? [0.03%]
杜普利尤单抗治疗特应性皮炎2017年获批后的新进展及未来方向？
Jorien van der Schaft,Judith L Thijs,Marjolein S de Bruin-Weller et al.
Jorien van der Schaft et al.
Purpose of review: The IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling new data regarding dupilumab published following the approva...
Jeanne D Johansen,Thomas Werfel
Jeanne D Johansen
Purpose of review: The purpose was to highlight recent findings especially concerning new and old allergens, trends, diagnosis and causes of contact allergy. ...